The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Preventing early disease progression in follicular lymphoma
While treatment for follicular lymphoma (FL) has improved in recent years, allowing most patients to have good outcomes, there remains a small subset of patients who experience disease progression within 24 months of chemoimmunotherapy. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, John Seymour, MBBS, FRACP, PhD, of the Peter MacCallum Cancer Center, Victoria, Australia, discusses the importance of identifying and treating these high risk patients. He gives an overview of existing prognostic indices, including FLIPI, FLIPI2 and the PRIMA prognostic index, as well as newer, more accurate methods that incorporate genetic screening, such as the m7-FLIPI and the POD24 predictive index. Finally, Dr Seymour touches upon the results from the GALLIUM study (NCT01332968), which show that early disease progression can be reduced with obinutuzumab.
